search
Back to results

The Impact of Different Citrate Concentrations as Locking Solutions on Development of Biofilm and Function of Hemodialysis Catheters

Primary Purpose

End-Stage Kidney Disease, Renal Dialysis, Central Venous Catheter

Status
Unknown status
Phase
Not Applicable
Locations
Slovenia
Study Type
Interventional
Intervention
4% sodium citrate
30% sodium citrate
Sponsored by
University Medical Centre Ljubljana
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for End-Stage Kidney Disease focused on measuring Dialysis catheters, Citrate, Locking solution

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • CKD on dialisys
  • AKI on dialisys

Exclusion Criteria:

  • systemic bacterial infection at the time of catheter insertion
  • local infection at the catheter insertion site
  • hypersensitivity to citrate
  • pregnancy

Sites / Locations

  • University Medical Centre Ljubljana, Ljubljana, SloveniaRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Experimental

Arm Label

4% citrate

30% citrate

Arm Description

dialysis catheter locked with 4% sodium citrate

dialysis catheter locked with 30% sodium citrate

Outcomes

Primary Outcome Measures

catheter dysfunction
occurrence of dysfunction of dialysis catheter (expressed as catheter days)

Secondary Outcome Measures

identification of microorganisms
investigators will identify potential microorganisms on the surfaces of the hemodialysis catheter by method "sonication" of the catheter segment and afterward cultivation in solid and liquid media
distribution of biofilm
investigators will inspect distribution of biofilm (% area) along inner surface of the dialysis catheter by electronic microscope

Full Information

First Posted
September 19, 2018
Last Updated
September 21, 2018
Sponsor
University Medical Centre Ljubljana
search

1. Study Identification

Unique Protocol Identification Number
NCT03683563
Brief Title
The Impact of Different Citrate Concentrations as Locking Solutions on Development of Biofilm and Function of Hemodialysis Catheters
Official Title
A Prospective, Interventional Study to Investigate the Impact of Different Citrate Concentrations as Locking Solutions on Development of Biofilm and Function of Hemodialysis Catheters
Study Type
Interventional

2. Study Status

Record Verification Date
September 2018
Overall Recruitment Status
Unknown status
Study Start Date
April 11, 2018 (Actual)
Primary Completion Date
April 2019 (Anticipated)
Study Completion Date
June 2019 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University Medical Centre Ljubljana

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Evidence that supports using certain concentration of trisodium citrate as a locking solution for hemodialysis catheters has not yet been established. Higher concentrations of trisodium citrate are more effective in preventing thrombosis, formation of blood clots, preventing infections and biofilm formation, but due to potential side effects, their use is limited. The aim of the study is to compare the impact of two different concentrations of tri-sodium citrate solution (30% and 4%) on the formation of biofilms in hemodialysis single-volume jugular hemodialysis catheters and to determine the effectiveness of prevention of dysfunction of hemodialysis catheters.
Detailed Description
AIM OF THE STUDY: The aim of the study is to compare the impact of two different concentrations of trisodium citrate solution (30% and 4%) on the formation of biofilms in hemodialysis single-volume jugular hemodialysis catheters and to determine the effectiveness of prevention of dysfunction of hemodialysis catheters. Investigators will compare the influence of two different concentrations of trisodium citrate solutions as a locking solutions for hemodialysis catheters on the formation of intraluminal biofilm, the growth of microorganisms in the lumen of the hemodialysis catheter, and the occurrence of dysfunction of hemodialysis catheters in the same patient at the same time, under the same conditions as the same length and volume of hemodialysis catheters, catheter insertion time, duration of dialysis procedures, sex, age, co-morbidity, therapy and the presence of an infection. BACKGROUND: The population of patients this study will include are the ones who are being treated or are supposed to start the hemodialysis treatment at the Center for Acute and Complicated Dialysis, Department for Nephrology, UKC Ljubljana and for vascular approach have newly inserted or for any reason newly replaced two single-hemodialysis catheter to the left or right inner jugular vein. STUDY DESIGN: The patients this study will include are the patients on chronic replacement therapy with hemodialysis, patients with acute renal failure who are on transient replacement therapy with hemodialysis and patients with renal failure starting with substitution treatment with chronic hemodialysis. After determining the eligibility for inclusion in our study, the investigators will acquire the written consent from the patient. Patients that will be included in the study will have simultaneously inserted two jugular catheters. In the inter-dialysis period, catheters will always be filled with one catheter with 30% trisodium citrate solution, another catheter with 4% tri-sodium citrate solution. The study will be conducted as a prospective interventional clinical trial. After dialysis, the patients' catheters will always be filled by the same protocol (one catheter with 30% trisodium citrate solution, the second catheter with 4% trisodium citrate solution). Patients will be allocated alternately between protocols 1 and 2. There are 2 protocols for filling dialysis catheters: Protocol 1: the upper (artery) catheter will be filled with 4% and lower (vein) with 30% trisodium citrate solution, Protocol 2: upper (artery) catheter will be filled with 30% and the lower (vein) with a 4% trisodium citrate solution. Among the patients included, investigators will compare the pressure in the extracorporeal system and blood flow through dialysis catheter, time to dysfunction of hemodialysis catheters, eventual infections associated with catheter: bacteremia or sepsis, infection of the exit of dialysis catheters using different concentrations of trisodium citrate as a locking solution in the inter-dialysis period. Among the patients included, investigators will also monitor the duration of dialysis treatment, the duration of the dialysis procedure in one week, the presence of infection, age, co-morbidity, concomitant therapy (treatment with anticoagulation and anti-aggregation drugs, the presence of immunosuppression, antibiotics). In approximately 5 patients we will simultaneously remove the dialysis catheter due to any medical indication and then via an electronic microscope and stereomicroscope evaluate morphological characteristics of biofilm. Investigators will also evaluate the microbiological characteristics of biofilms using microbiological methods. EXPECTED RESULTS: It is expected that the occurrence of dysfunction or the number of catheter days in the same patients using different concentrations of trisodium citrate solutions in inter-dialysis period will be statistically different. It is expected that the morphological parameters of biofilm will be statistically different using different concentration solution of trisodium citrate (30%, 4%). It is also expected that the microbiological characteristics of biofilm will differ according to the used concentration of the trisodium citrate solution in the inter-dialysis period. The data investigators will receive can help to understand the adverse events occurring with the use of hemodialysis catheters, filling with different concentrations of trisodium citrate solutions.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
End-Stage Kidney Disease, Renal Dialysis, Central Venous Catheter, Biofilms
Keywords
Dialysis catheters, Citrate, Locking solution

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
50 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
4% citrate
Arm Type
Active Comparator
Arm Description
dialysis catheter locked with 4% sodium citrate
Arm Title
30% citrate
Arm Type
Experimental
Arm Description
dialysis catheter locked with 30% sodium citrate
Intervention Type
Other
Intervention Name(s)
4% sodium citrate
Intervention Description
the catheter will be locked with 4% citrate solution after each dialysis session
Intervention Type
Other
Intervention Name(s)
30% sodium citrate
Intervention Description
the catheter will be locked with 30% citrate solution after each dialysis session
Primary Outcome Measure Information:
Title
catheter dysfunction
Description
occurrence of dysfunction of dialysis catheter (expressed as catheter days)
Time Frame
within 6 months after catheter insertion
Secondary Outcome Measure Information:
Title
identification of microorganisms
Description
investigators will identify potential microorganisms on the surfaces of the hemodialysis catheter by method "sonication" of the catheter segment and afterward cultivation in solid and liquid media
Time Frame
an average of 1 year
Title
distribution of biofilm
Description
investigators will inspect distribution of biofilm (% area) along inner surface of the dialysis catheter by electronic microscope
Time Frame
an average of 1 year

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: CKD on dialisys AKI on dialisys Exclusion Criteria: systemic bacterial infection at the time of catheter insertion local infection at the catheter insertion site hypersensitivity to citrate pregnancy
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Bojan Medved, MD
Phone
+38670609667
Email
bojan.medved@kclj.si
Facility Information:
Facility Name
University Medical Centre Ljubljana, Ljubljana, Slovenia
City
Ljubljana
ZIP/Postal Code
1000
Country
Slovenia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Bojan Medved, MD
Phone
+38670609667
Email
bojan.medved@kclj.si

12. IPD Sharing Statement

Plan to Share IPD
Undecided

Learn more about this trial

The Impact of Different Citrate Concentrations as Locking Solutions on Development of Biofilm and Function of Hemodialysis Catheters

We'll reach out to this number within 24 hrs